Pharma Taken By EU Pilot On Merging MRP/DCP Lines
This article was originally published in SRA
Executive Summary
Drug companies have shown a huge interest in part of an EU pilot project that allows them to merge licences under the mutual recognition and decentralized procedures to suit their business strategies1,2. Generic and OTC drug makers submitted over 60 applications for merging their MRP/DCP lines, of which 10 have been admitted in accordance with the maximum permissible limit of the pilot.
You may also be interested in...
EU Extends Pilot On Splitting Mutual Recognition/Decentralized Procedures
Drug companies in the EU are getting more time to experiment with splitting their mutual recognition and decentralized procedure licences to help with their marketing strategies.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.